Autoantibody-induced formation of immune complexes in normal human serum

Current Pharmaceutical Design

Volumn 12, Issue 2, 2006, Pages 173-179

  Lemieux, Réal ^a   Bazin, Renée ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

Autoantibody; Autoimmune disease; Immune complex; IVIg; Plasma

Indexed keywords

ALPHA INTERFERON; ANTIIDIOTYPIC ANTIBODY; AUTOANTIBODY; BLOOD CLOTTING FACTOR 8 ANTIBODY; CD4 ANTIGEN; CD5 ANTIGEN; COMPLEMENT; DNA ANTIBODY; FERRITIN ANTIBODY; FIBRINOGEN RECEPTOR ANTIBODY; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 1ALPHA; T LYMPHOCYTE RECEPTOR; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; AFFINITY CHROMATOGRAPHY; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN ANTIBODY REACTION; ANTIGEN PURIFICATION; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INNATE IMMUNITY; MACROPHAGE ACTIVATION; MEMORY CELL; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY; PLASMA; PRIORITY JOURNAL; REVIEW; WESTERN BLOTTING; ANIMAL; ANTIBODY PRODUCTION; BIOSYNTHESIS; BLOOD; DRUG EFFECT; IMMUNOLOGY;

ANIMALS; ANTIBODY FORMATION; ANTIGEN-ANTIBODY COMPLEX; AUTOANTIBODIES; HUMANS; IMMUNOGLOBULIN G;

EID: 33644861543     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206775193055     Document Type: Review

References (83)

1. Pi D, Petraszko T. IVIG supply and cost. In: IVIG utilization management handbook. First Edition ed: Provincial Blood Coordinating Office, Vancouver www.bloodlink.bc.ca; 2002; p. 1-3.
2. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981; 1(8232): 1228-31.
3. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001; 345(10): 747-55.
4. Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 2002; 59(12 Suppl 6): S13-21.
5. Koski CL. Therapy of CIDP and related immune-mediated neuropathies. Neurology 2002; 59(12 Suppl 6): S22-7.
6. Knezevic-Maramica I, Kruskall MS. Intravenous immune globulins: an update for clinicians. Transfusion 2003; 43(10): 1460-80.
7. Sorensen PS. Treatment of multiple sclerosis with intravenous immunoglobulin: review of clinical trials. Neurol Sci 2003; 24 (Suppl 4): S227-30.
8. Lemieux R, Bazin R, Néron S. Therapeutic intravenous immunoglobulins. Mol Immunol 2005; 42(7): 839-48.
9. Bayry J, Thirion M, Misra N, Thorenoor N, Delignat S, Lacroix-Desmazes S, et al. Mechanisms of action of intravenous immunoglobulin in autoimmune and inflammatory diseases. Neurol Sci 2003; 24(Suppl 4): S217-21.
10. Lazarus AH, Crow AR. Mechanism of action of IVIG and anti-D in ITP. Transfus Apheresis Sci 2003; 28(3): 249-5050.0
11. Tonegawa S. Somatic generation of antibody diversity. Nature 1983; 302(5909): 575-81.
12. Burnet FM. A modification of Jerne's theory of antibody production using the concept of clonal selection. Austral J Sci 1957; 20: 67-69.
13. Niiro H, Clark EA. Regulation of B-cell fate by antigen-receptor signals. Nat Rev Immunol 2002; 2(12): 945-56.
14. Ehrlich P. On immunity with special reference to cell life. Proc Roy Soc Lond 1900; 66: 424-448.
15. Roitt IM, Hutchings PR, Dawe KI, Sumar N, Bodman KB, Cooke A. The forces driving autoimmune disease. J Autoimmun 1992; 5 (Suppl A): 11 -26.
16. Nemazee DA, Burki K. Clonal deletion of B lymphocytes in a transgenic mouse bearing anti-MHC class I antibody genes. Nature 1989; 337(6207): 562-6.
17. Russell DM, Dembic Z, Morahan G, Miller JF, Burki K, Nemazee D. Peripheral deletion of self-reactive B cells. Nature 1991; 354(6351): 308-11.
18. Goodnow CC, Crosbie J, Adelstein S, Lavoie TB, Smith-Gill SJ, Brink RA, et al. Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature 1988; 334(6184): 676-82.
19. Adams E, Basten A, Goodnow CC. Intrinsic B-cell hyporesponsiveness accounts for self-tolerance in lysozyme/anti-lysozyme double-transgenic mice. Proc Natl Acad Sci USA 1990; 87(15): 5687-91.
20. Gay D, Saunders T, Camper S, Weigert M. Receptor editing: an approach by autoreactive B cells to escape tolerance. J Exp Med 1993; 177(4): 999-1008.
21. Tiegs SL, Russell DM, Nemazee D. Receptor editing in self-reactive bone marrow B cells. J Exp Med 1993; 177(4): 1009-20.
22. Hayakawa K, Asano M, Shinton SA, Gui M, Allman D, Stewart CL, et al. Positive selection of natural autoreactive B cells. Science 1999; 285(5424): 113-6.
23. Julien S, Soulas P, Garaud JC, Martin T, Pasquali JL. B cell positive selection by soluble self-antigen. J Immunol 2002; 169(8): 4198-204.
24. Landsteiner K. The specificity of serological reactions. Cambridge, Massachusetts 1945.
25. Boyden SV. Natural antibodies and the immune response. Adv Immunol 1965; 5: 1-28.
26. Lacroix-Desmazes S, Kaveri SV, Mouthon L, Ayouba A, Malanchere E, Coutinho A, et al. Self-reactive antibodies (natural autoantibodies) in healthy individuals. J Immunol Methods 1998; 216(1-2): 117-37.
27. Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med 2000; 343(1): 37-49.
28. Medzhitov R, Janeway CA, Jr. Innate immune recognition and control of adaptive immune responses. Semin Immunol 1998; 10(5): 351-3.
29. Winchester RJ, Fu SM, Winfield JB, Kunkel HG. Immunofluorescent studies on antibodies directed to a buried membrane structure present in lymphocytes and erythrocytes. J Immunol 1975; 114(1 Pt 2): 410-4.
30. Lutz HU, Wipf G. Naturally occurring autoantibodies to skeletal proteins from human red blood cells. J Immunol 1982; 128(4): 1695-9.
31. Karsenti E, Guilbert B, Bornens M, Avrameas S. Antibodies to tubulin in normal nonimmunized animals. Proc Natl Acad Sci USA 1977; 74(9): 3997-4001.
32. Wass M, McCann K, Bagshawe KD. Isolation of antibodies to HCG/LH from human sera. Nature 1978; 274(5669): 369-70.
33. Mihaescu S, Lenkei R, Ghetie V. Radioimmunoassay of anti-albumin autoantibodies in human sera. J Immunol Methods 1981: 42(2): 187-93.
34. Guilbert B, Dighiero G, Avrameas S. Naturally occurring antibodies against nine common antigens in human sera. I. Detection, isolation and characterization. J Immunol 1982. 128(6): 2779-87.
35. Dresser DW. Most IgM-producing cells in the mouse secrete autoantibodies (rheumatoid factor). Nature 1978; 274(5670): 480-3.
36. Cunningham AJ. Large numbers of cells in normal mice produce antibody components of isologous erythrocytes. Nature 1974; 252(5485): 749-51.
37. Haspel MV, Onodera T, Prabhakar BS, McClintock PR, Essani K, Ray UR, et al. Multiple organ-reactive monoclonal autoantibodies. Nature 1983; 304(5921): 73-6.
38. Dighiero G, Lymberi P, Mazie JC, Rouyre S, Butler-Browne GS, Whalen RG, et al. Murine hybridomas secreting natural monoclonal antibodies reacting with self antigens. J Immunol 1983; 131(5): 2267-72.
39. Cairns E, Block J, Bell DA. Anti-DNA autoantibody-producing hybridomas of normal human lymphoid cell origin. J Clin Invest 1984; 74(3): 880-7.
40. Robinson JE, Stevens KC. Production of autoantibodies to cellular antigens by human B cells transformed by Epstein-Barr virus. Clin Iummunol Immunopathol 1984; 33(3): 339-50.
41. Logtenberg T, Kroon A, Gmelig-Meyling FH, Ballieux RE. Analysis of the human tonsil B cell repertoire by somatic hybridization: occurrence of both "monospecific" and "multispecific" (auto)antibody-secreting cells. Eur J Immunol 1987; 17(6): 855-9.
42. Casali P, Burastero SE, Nakamura M, Inghirami G, Notkins AL. Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. Science 1987; 236(4797): 77-81.
43. Seigneurin JM, Guilbert B, Bourgeat MJ, Avrameas S. Polyspecific natural antibodies and autoantibodies secreted by human lymphocytes immortalized with Epstein-Barr virus. Blood 1988; 71(3): 581-5.
44. Adib M, Ragimbeau J, Avrameas S, Ternynck T. IgG autoantibody activity in normal mouse serum is controlled by IgM. J Immunol 1990; 145(11): 3807-13.
45. Hurez V, Kaveri SV, Kazatchkine MD. Expression and control of the natural autoreactive IgG repertoire in normal human serum. Eur J Immunol 1993; 23(4): 783-9.
46. Berneman A, Guilbert B, Eschrich S, Avrameas S. IgG auto- and polyreactivities of normal human sera. Mol Immunol 1993; 30(16): 1499-510.
47. Nasu H, Chia DS, Knutson DW, Barnett EV. Naturally occurring human antibodies to the F(ab')2 portion of IgG. Clin Exp Immunol 1980; 42(2): 378-86.
48. Rossi F, Dietrich G, Kazatchkine MD. Anti-idiotypes against autoantibodies in normal immunoglobulins: evidence for network regulation of human autoimmune responses. Immunol Rev 1989; 110: 135-49.
49. Hunt Gerardo S, Persselin JE, Stevens RH. Human IgG anti-F(ab')2 antibodies possess rheumatoid factor activity. Clin Exp Immunol 1990; 81(2): 293-300.
50. Dietrich G, Kaveri SV, Kazatchkine MD. A V region-connected autoreactive subfraction of normal human serum immunoglobulin G. Eur J Immunol 1992; 22(7): 1701-6.
51. Ballow M. Intravenous immunoglobulins: clinical experience and viral safety. J Am Pharm Assoc 2002; 42(3): 449-59.
52. Emmenegger U, Frey U, Reimers A, Fux C, Semela D, Cottagnoud P, et al. Hyperferritinemia as indicator for intravenous immunoglobulin treatment in reactive macrophage activation syndromes. Am J Hematol 2001; 68(1): 4-10.
53. Lamoureux J, Aubin E, Lemieux R. Autoimmune complexes in human serum in presence of therapeutic amounts of intravenous immunoglobulins. Blood 2003; 101(4): 1660-2.
54. Day NK Good RA, Wahn V. Adverse reactions in selected patients following intravenous infusions of gamma globulin. Am J Med 1984; 76(3A): 25-32.
55. Cunningham-Rundles C, Carr RI. Dietary bovine antigens and immune complex formation after intravenous immunoglobulin in common varied immunodeficiency. J Clin Immunol 1986; 6(5): 381-8.
56. Gyongyossy-Issa MI, Carter CJ, Racaza A, Devine DV. IVIG treatment causes plasma hyperviscosity, circulating immune complexes and complement activation in ITP and CIDP patients. Transfusion 2004; 44(9S): 133A.
57. Clynes R, Maizes JS, Guinamard R, Ono M, Takai T, Ravetch JV. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J Exp Med 1999, 189(1): 179-85.
58. Lutz HU, Stammler P, Bianchi V, Trueb RM, Hunziker T, Burger R, et al. Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level. Blood 2004; 103(2): 465-72.
59. Lamoureux J, Aubin E, Lemieux R. Autoantibodies purified from therapeutic preparations of intravenous immunoglobulins (IVIg) induce the formation of autoimmune complexes in normal human serum: a role in the in vivo mechanisms of action of IVIg? Int Immunol 2004; 16(7): 929-36.
60. Bruley-Rosset M, Mouthon L, Chanseaud Y, Dhainaut F, Lirochon J, Bourel D. Polyreactive autoantibodies purified from human intravenous immunoglobulins prevent the development of experimental autoimmune diseases. Lab Invest 2003; 83(7): 1013-23.
61. Bayry J, Lacroix-Desmazes S, Donkova-Petrinj V, Carbonnel C, Misra N, Lepelletier Y, et al. Natural antibodies sustain differentiation and maturation of human dendritic cells. Proc Natl Acad Sci USA 2004; 101 (39): 14210-5.
62. Bazin R, Lemieux R, Tremblay T, St-Amour I. Tetramolecular immune complexes are more efficient than IVIg to prevent antibody-dependent in vitro and in vivo phagocytosis of blood cells. Br J Haematol 2004; 127(1): 90-6.
63. Schluter SF, Adelman MK, Taneja V, David C, Yocum DE, Marchalonis JJ. Natural autoantibodies to TCR public idiotopes: potential roles in immunomodulation. Cell Mol Biol (Noisy-le-grand) 2003; 49(2): 193-207.
64. Hurez V, Kaveri SV, Mouhoub A, Dietrich G, Mani JC, Klatzmann D, et al. Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg). Ther Immunol 1994; 1(5): 269-77.
65. Vassilev T, Gelin C, Kaveri SV, Zilber MT, Boumsell L, Kazatchkine MD. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol, 1993; 92(3): 369-72.
66. Kaveri S, Vassilev T, Hurez V, Lengagne R, Lefranc C, Cot S, et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996; 97(3): 865-9.
67. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282(5388): 490-3.
68. Prasad NK, Papoff G, Zeuner A, Bonnin E, Kazatchkine MD, Ruberti G, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998. 161(7): 3781-90.
69. Wadhwa M, Meager A, Dilger P, Bird C, Dolman C, Das RG, et al. Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1 alpha and interferon-alpha but not other cytokines in human immunoglobulin preparations. Immunology 2000; 99(1): 113-23.
70. Menezes MC, Benard G, Sato MN, Hong MA, Duarte AJ. In vitro inhibitory activity of tumor necrosis factor alpha and interleukin-2 of human immunoglobulin preparations. Int Arch Allergy Immunol 1997; 114(4): 323-8.
71. Toungouz M, Denys C, Dupont E. Blockade of proliferation and tumor necrosis factor-alpha production occurring during mixed lymphocyte reaction by interferon-gamma-specific natural antibodies contained in intravenous immunoglobulins. Transplantation 1996; 62(9): 1292-6.
72. Sultan Y, Kazatchkine MD, Maisonneuve P, Nydegger UE. Anti-idiotypic suppression of autoantibodies to factor VIII (antihaemophilic factor) by high-dose intravenous gammaglobulin. Lancet 1984; 2(8406): 765-8.
73. Dietrich G, Pereira P, Algiman M, Sultan Y, Kazatchkine MD. A monoclonal anti-idiotypic antibody against the antigen-combining site of anti-factor VIII autoantibodies defines and idiotope that is recognized by normal human polyspecific immunoglobulins for therapeutic use (IVIg). J Autoimmun 1990; 3(5): 547-57.
74. Rossi F, Kazatchkine MD. Antidiotypes against autoantibodies in pooled normal human polyspecific Ig. J Immunol 1989; 143(12): 4104-9.
75. Evans MJ, Suenaga R, Abdou NI. Detection and purification of antiidiotypic antibody against anti-DNA in intravenous immune globulin. J Clin Immunol 1991; 11(5): 291-5.
76. Silvestris F, Cafforio P, Dammacco F. Pathogenic anti-DNA idiotype-reactive IgG in intravenous immunoglobulin preparations. Clin Exp Immunol 1994; 97(1): 19-25.
77. Berchtold P, Dale GL, Tani P, McMillan R. Inhibition of autoantibody binding to platelet glycoprotein IIb/IIIa by anti-idiotypic antibodies in intravenous gammaglobulin. Blood 1989; 74(7): 2414-7.
78. Dietrich G, Kazatchkine MD. Normal immunoglobulin G (IgG) for therapeutic use (intravenous Ig) contain antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest 1990; 85(3): 620-5.
79. Basta M, Van Goor F, Luccioli S, Billings EM, Vortmeyer AO, Baranyi L, et al. F(ab)'2-mediated 'neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins. Nat Med 2003; 9(4): 431-8.
80. Vassilev TL, Kazatchkine MD, Van Huyen JP, Mekrache M, Bonnin E, Mani JC, et al. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 1999; 93(11): 3624-31.
81. Kleinau S. The impact of Fc receptors on the development of autoimmune diseases. Curr Pharm Design 2003; 9(23): 1861-70.
82. Ruiz-Arguelles A, Rivadeneyra-Espinoza L, Alarcon-Segovia, D. Antibody penetration into living cells: pathogenic, preventive and immuno-therapeutic implications. Curr Pharm Design 2003; 9(23): 1881-7.
83. Stahl D, Sibrowski W. Regulation of the immune response by natural IgM: lessons from warm autoimmune hemolytic anemia. Curr Pharm Design 2003; 9(23): 1871-80.